丹麦外用抗银屑病药物的使用:一项全国性药物利用研究
基于丹麦全国健康登记数据,纳入2005-2015年首次获得医院银屑病诊断并至少配取一次外用药物处方的7743例患者,随访3年。外用药物总使用量下降19%,甲氨蝶呤使用增加70%,生物制剂使用率最高达6%,外用药物使用在时间、地区和患者间存在显著异质性。
要点
- 外用药物使用以强效糖皮质激素(30%)和含钙泊三醇的糖皮质激素(31%)为主。
- 研究期间外用药物总体使用量下降19%,甲氨蝶呤使用增加70%。
- 25%的患者使用了70%的外用药物总量,地区差异明显。
核心结论
- 研究进一步证明外用抗银屑病药物的使用在时间、地区实践和患者之间存在显著异质性。
研究设计与样本
- 基于丹麦全国健康登记数据的药物利用研究,纳入2005-2015年首次获得医院银屑病诊断并至少配取一次外用药物处方的患者7743例,随访3年。
主要发现
- 外用药物总使用分布为:含钙泊三醇的糖皮质激素31%、钙泊三醇6.5%、极强效糖皮质激素24%、强效糖皮质激素30%、中效糖皮质激素7.2%、含抗菌药的糖皮质激素1.6%。
- 研究期间外用药物总体使用量下降19%。
- 诊断前后外用药物使用增加,多数患者在诊断后第一年配取超过2包外用药物。
- 患者外用药物使用存在明显地区差异,25%的患者使用了70%的外用药物总量。
- 研究期间甲氨蝶呤使用增加70%,生物制剂使用率最高达6%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The reported real-life use of prescribed topical antipsoriatic drugs is conflicting and based on heterogeneous data sources. OBJECTIVES: To describe the utilization of topical antipsoriatic drugs among patients with psoriasis in Denmark. METHODS: A drug utilization study was performed based on nationwide Danish health registry data. We identified patients who received a first-time hospital diagnosis of psoriasis and redeemed at least one topical drug prescription in the period 2005-2015 (n = 7743). Patients were followed for 3 years from the time of diagnosis. Use of topical and systemic antipsoriatic drugs was described, specified by the type of treatment. RESULTS: The total use of topical drugs was divided between corticosteroids with calcipotriol (31%), calcipotriol (6·5%), very potent corticosteroids (24%), potent corticosteroids (30%), moderate corticosteroids (7·2%) and corticosteroids with antimicrobials (1·6%). There was a 19% reduction in the overall use of topical drugs during the study period. Use increased around the time of diagnosis and the majority of patients redeemed more than two packages of topical drugs during the first year after being diagnosed. Regional differences in patients' use of topical drugs varied considerably. The distribution of use of topical drugs was uneven, with a minority of all patients (25%) using 70% of the total amount of topical treatment. There was a 70% increase in the use of methotrexate over the study period. Biologics were used by up to 6%. CONCLUSIONS: The study provides further evidence that the use of topical antipsoriatic drugs shows considerable heterogeneity over time and regional practices, and differences between patients.
引用
- Svendsen MT, Ernst MS, Andersen KE, et al. Use of topical antipsoriatic drugs in Denmark: a nationwide drug utilization study. Br J Dermatol. 2018. PMID: 30098007. doi:10.1111/bjd.17074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。